Search hospitals > New York > New York
Weill Cornell Medical College
Claim this profileNew York, New York 10065
Global Leader in Lymphoma
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Cancer
Conducts research for Prostate Cancer
Conducts research for Prostatic Neoplasm
1175 reported clinical trials
224 medical researchers
Summary
Weill Cornell Medical College is a medical facility located in New York, New York. This center is recognized for care of Lymphoma, Adult T-Cell Leukemia/Lymphoma, Cancer, Prostate Cancer, Prostatic Neoplasm and other specialties. Weill Cornell Medical College is involved with conducting 1,175 clinical trials across 1,667 conditions. There are 224 research doctors associated with this hospital, such as Pashtoon Kasi, MS, Alexander J. Chou, Koen Van Besien, MD, and Scott Tagawa, MD.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage II
Stage III
2Adult T-Cell Leukemia/Lymphoma
Global LeaderFLT3 positive
CD5 positive
Stage II
Top PIs
Pashtoon Kasi, MSUniversity of Iowa/Holden Comprehensive Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Cervical Adenocarcinoma
19 reported clinical trials
48 drugs studied
Alexander J. ChouNYP/Weill Cornell Medical Center8 years of reported clinical research
Expert in Cancer
Expert in Lymphoma
17 reported clinical trials
39 drugs studied
Koen Van Besien, MDWeill Cornell Medical College7 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Lymphoma
15 reported clinical trials
23 drugs studied
Scott Tagawa, MDWeill Cornell Medical College4 years of reported clinical research
Expert in Prostate Cancer
Expert in Prostatic Neoplasm
14 reported clinical trials
32 drugs studied
Clinical Trials running at Weill Cornell Medical College
Lymphoma
Breast Cancer
Prostate Cancer
Myelofibrosis
Heart Failure
Multiple Myeloma
Lung Cancer
Brain Tumor
Colon Cancer
Mantle Cell Lymphoma
Long-term Ibrutinib
for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Recruiting2 awards Phase 35 criteria
Glofitamab + Pola-R-CHP
for B-Cell Lymphoma
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Recruiting2 awards Phase 39 criteria
Axicabtagene Ciloleucel
for Lymphoma
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Weill Cornell Medical College?
Where is Weill Cornell Medical College located?
Who should I call to ask about financial aid or insurance network?
What insurance does Weill Cornell Medical College accept?
What awards or recognition has Weill Cornell Medical College received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.